Progress in SCLC: From Deadly to Cure?
Millie Das, MD, of Stanford Cancer Center, discusses the progress in small cell lung cancer treatment.
Source: onclive.com
📰 Millie Das News
Millie Das News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Millie Das. Real-time updates on events, politics, business and more.
TKIs, Immunotherapy, and ADCs Amplify the SCLC and NSCLC Treatment Paradigms
Millie Das, MD, highlights early efficacy signals with PARP inhibitors in patients with small cell lung cancer, how overall survival data from the phase 3 ADAURA trial confirm the efficacy of adjuvant osimertinib in patients with non–small cell lung cancer, and which patients may benefit most from immunotherapy as monotherapy or in combination with other agents.
Source: onclive.com
Experts Provide Key Perspectives on the US Cisplatin/Carboplatin Shortage
Experts from various institutions were interviewed by OncLive® at the 24th Annual International Lung Cancer Congress® about the ongoing platinum chemotherapy shortage in the United States.
Source: onclive.com
Dr Das on the Landscape of Current and Emerging ADCs in SCLC
Millie Das, MD, discusses the current landscape of new and emerging ADCs under investigation in small-cell lung cancer and highlights the phase 2 SWOG S1929 study.
Millie Das Lung Cancer Working Group Stanford Cancer Center Lung Cancer Precision Oncology Program Palo Alto
Source: onclive.com